Biodesix Receives US Patents Covering VeriStrat Test
April 15, 2011
Biodesix Receives US Patents Covering VeriStrat Test
The patents cover the selection of non-small cell lung cancer patients, colorectal cancer patients, and head and neck cancer patients for treatment with drugs targeting the epidermal growth-factor receptor pathway.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Biodesix Raises $7.1M in Series C Financing Round
November 12, 2010 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor - GenomeWeb Feature: The Unsteady March of Cancer Protein Biomarkers into the Clinic
May 10, 2013 / ProteoMonitor